J&J Gets FDA OK of Stelara for Pediatric Patients With Active Psoriatic Arthritis
02 August 2022 - 12:06AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on
Monday said the U.S. Food and Drug Administration approved the
expanded use of its blockbuster anti-inflammatory drug Stelara to
treat children ages six and older with active psoriatic
arthritis.
The company said two of the four FDA-approved indications for
Stelara now include pediatric patients.
The agency first approved Stelara in September 2009 for adults
with moderate to severe plaque psoriasis, and the drug has since
been cleared for use in psoriatic arthritis, Crohn's disease and
ulcerative colitis.
Johnson & Johnson reported second-quarter Stelara sales of
nearly $2.6 billion.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 01, 2022 09:51 ET (13:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2023 to Mar 2024